Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Li-Fei Zhou
Total Records ( 2 ) for Li-Fei Zhou
  Li-Fei Zhou , Fu-Gen He , Bai-Zhen Lu and Feng-Yang Chen
  Shaoyao Ruangan Heji (SYRG), a liquid pharmaceutical formulation of traditional Chinese medicine, has been used clinically for the prevention and treatment of chemotherapy-induced liver injury in Zhejiang Cancer Hospital (China) for 37 years. However, its underlying therapeutic mechanism is still unclear. Because oxidative stress is a crucial etiological factor implicated in the pathology of chemotherapy-induced liver injury, in this study, the protective effect of SYRG on carbon tetrachloride (CCl4)-induced oxidative stress and liver injury in mice were evaluated and its mechanisms were investigated by Mouse Stress and Toxicity Pathway Finder PCR Array. The results showed that pretreatment with SYRG significantly attenuated CCl4-induced liver damage in mice, evidenced by decreased serum enzyme activities of ALT and AST, which was also supported by the histopathological examination of the mice liver. The SYRG also showed a significant protective effect against CCl4-induced hepatic MDA elevation and depletion of T-AOC, SOD and GSH content. Furthermore, SYRG regulated 25 genes related to six stress and toxicity pathways (Oxidative stress, hypoxia, cell necrosis, inflammatory response, DNA damage signaling and heat shock proteins/unfolded protein response) in the impaired liver induced by CCl4. These results indicated that SYRG has protective effects against CCl4-induced liver injury and its underlying mechanisms involve the modulation of multiple stress and toxicity pathways. These findings would be beneficial for understanding of the therapeutic effects of SYRG in treatment of chemotherapy-induced liver injure in clinic.
  Feng-Yang Chen , Li-Fei Zhou , Xiao-Yu Li , Shi-Fang Xu , Li-Juan Gao , Hong-Xiang Sun and Yi-Ping Ye
  Background and Objective: Stephanthraniline A (STA), a natural C21 steroid isolated from Stephanotis mucronata (Blanco) Merr., is a potential immunosuppressant. The purpose of this study was to investigate the synergetic effects of STA and cyclosporine A (CsA) on T-cell response. Materials and Methods: First, the synergetic effects of STA and CsA were investigated in vitro on the cell proliferation, CD25 surface expression and cytokine IL-2 production of concanavalin A (Con A)-induced T-cells by MTT method, flow cytometric analysis and ELISA, respectively. Furthermore, 2,4-dinitrofluorobenzene (DNFB)-induced delayed-type hypersensitivity (DTH), a T-cell-mediated response in mice was used to evaluate the synergetic effects of STA and CsA in vivo. Finally, the direct effect of STA on CYP3A4, which is the predominant enzyme for metabolism of CsA was determined using P450-Glo™ CYP3A4 screening system. Results: The results showed that Con A-induced T-cells proliferation, IL-2 production and CD25 expression were not inhibited by low-dose STA (1 μM) or CsA (1 nM) alone but was significantly reduced by the combination of STA and CsA. The DNFB-induced mice ear swelling, hyperplasia and infiltration of inflammatory cells were also significantly diminished by the combined treatment with non-therapeutic dose of STA (1 mg kg–1) and CsA (0.5 mg kg–1). In addition, STA at the concentration of more than 0.1 μM significantly decreased CYP3A4 activity. Conclusion: The STA synergized the inhibitory effects of CsA on T-cell response in vitro and in vivo. These effects were attributable to its different and complementary molecular mechanisms and may partly due to its increasing of the bioavailability of CsA via inhibiting CYP3A4.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility